"Night Vision and Carotenoids"

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

27 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-02-13

Study Completion Date

2020-08-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Vision at twilight and night is more difficult and dangerous for the entire population, even more so for the elderly and especially for the elderly with degenerative disease. Multiple worldwide laboratories have demonstrated the ability to raise macular pigment optical density with dietary carotenoids. This proposal further evaluates the relationship between macular re- pigmentation and vision under stressed conditions simulating twilight and night driving.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Carotenoid Supplementation and Normal Ocular Health

NCT02147171

Retinal Ageing

COMPLETED PHASE2/PHASE3

Eye and Carotenoid Augmentation Research and Evaluation (EyeCARE)

NCT06848101

Vision Eye Health

ACTIVE_NOT_RECRUITING NA

Carotenoid Supplementation and Retinal Health in Healthy Adults

NCT07314411

Healthy

RECRUITING NA

Macular Pigment Measurements in Eye & Other Tissues

NCT03022773

Macular Pigmentation Skin Pigment

ENROLLING_BY_INVITATION NA

Natural History, Pathogenesis, and Outcome of Ocular Disorders

NCT02821767

Eye Disease

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a study of the physiological function of the eyes at night. However, the risk of automobile injury or fatality (driver, passenger or pedestrian) associated with motor vehicle accidents has been determined to increase with age, as a result of the complex interplay of age-related declines in vision, motor and cognitive functioning. However, basic visual function is the foundation for higher order processing whether it is visual spatial or cognitive. Four recent studies reflect the cost of poor vision on driving. (www.visionimpactinstitute.org). For example, visual impairment among European drivers was examined in 2422 drivers from 5 European countries. Visual acuity, visual field, contrast sensitivity, glare sensitivity, and useful field of view were tested. Visual functions not included in the current licensing standards were found to be more impaired among drivers (compared to those functions legally required). Elderly drivers are particularly vulnerable to sensory visual impairment when driving at night, as they suffer declines in both Contrast sensitivity (CS), Glare Disability (GD) and Glare Recovery (GR).6

Justification for study involving humans

Carotenoid science is well developed with respect to the safe utilization of dietary lutein (L) /zeaxanthin (Zx) as studied by the National Institute of Health (NEI). The recently published NEI AREDS2 study- May 2013, further substantiated the safety and usefulness of prescribing the carotenoids (10 mg L / 2 mg Zx) in patients at high risk of AMD. 7 Significantly, the average American and veteran population are typically low dose consumer of these carotenoids (1 to 2 mg/day for the average American).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Macular Degeneration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Capsule type that results in null or increased MPOD (macular pigment optical density in du -density units) - either Maltodextrin Placebo or OTC commercial "Night Vision Formulation" consisting of 21 mg carotenoid capsule (14 mg zeaxanthin and 7mg lutein) supplied by www.zeavision.com (Chesterfield, MO) in research coded bottles with code held by the company. Gel caps will be supplied in a single 180 count bottle. 1 gel cap per day will be taken with a meal. Subjects will be called by telephone to improve compliance. Supplement compliance will ultimately be gauged by the number of tablets returned.

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Research coded bottles with code held by the sponsor. Gel caps will be supplied in a single 180 count bottle. 1 gel cap per day will be taken with a meal.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Maltodextrin Placebo: Experimental is 1:2

Group Type PLACEBO_COMPARATOR

EyePromise Visual Edge

Intervention Type DIETARY_SUPPLEMENT

A dietary eye supplement containing 8 mg zeaxanthin and 4 mg lutein and additional proprietary nutrients

Active

Eye Promise Visual Edge containing 8 mg zeaxanthin \& 4 mg lutein Placebo: Experimental is 1:2

Group Type EXPERIMENTAL

EyePromise Visual Edge

Intervention Type DIETARY_SUPPLEMENT

A dietary eye supplement containing 8 mg zeaxanthin and 4 mg lutein and additional proprietary nutrients

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

EyePromise Visual Edge

A dietary eye supplement containing 8 mg zeaxanthin and 4 mg lutein and additional proprietary nutrients

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* No significant supplementary carotenoids within last 10 weeks. Without significant media opacity, cataract or congenital / acquired retinal disease other than atrophic AMD or diabetic retinopathy. Minimum 20/25 to enroll.

Exclusion Criteria

* Unwilling or medically / psychiatrically unable to take part in a 6 month study.
* Recent ophthalmologic surgery or treatment.
* Tricare, Retirees \& Enlisted Navy Personnel excluded. Already taking an OTC product to improve their night vision (containing carotenoids, polyphenols like bilberry).

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No